pharma · Non-Muscle Invasive Bladder Urothelial Carcinoma · Nasopharyngeal Cancinoma (NPC)
Chongqing Daxin Pharmaceutical
Chongqing Claruvis Pharmaceutical Co.,
Chongqing Claruvis Pharmaceutical is a pharma organization headquartered in CN. Primary therapeutic focus areas include Non-Muscle Invasive Bladder Urothelial Carcinoma, Nasopharyngeal Cancinoma (NPC). NovaPharmaNews lin
Chongqing, CN HQ
5 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Chongqing, CN
- Employees
- 5
- Programs
- 2
- Drugs
- 6
- Patents
- 0
metronomic adjuvant chemotherapy with capecitabine
Phase 3 · small molecule · Nasopharyngeal Cancinoma (NPC)
metronomic adjuvant chemotherapy with capecitabine for Nasopharyngeal Cancinoma (NPC) is a Phase 3 program (small_molecule) at Chongqing Claruvis Pharmaceutical Co., with 1 ClinicalTrials.gov record(s).
Internal code CZLL2025-031-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Chongqing Claruvis Pharmaceutical Co.,
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Nasopharyngeal Cancinoma (NPC)
- Status
- active
- Trials
- 1